Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZR-02-01 Matrix Fentanyl Patch for Cancer Pain
NCT00126789Phase 3Terminated
- Sponsor
- ZARS Pharmaceuticals
- Start
- Aug 2005
- Primary completion
- Jul 2007
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ZR-02-01 in cancer pain, sponsored by ZARS Pharmaceuticals. Primary endpoint: Number of participants with adverse events at 12 weeks. Started Aug 2005; status: terminated.
02
Drugs
ZR-02-01
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT00126789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126789.